Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Finn, Richard S.; Kudo, Masatoshi; Cheng, Ann Lii; Wyrwicz, Lucjan; Ngan, Rkc; Blanc, J.-F.; Baron, Ari David; Vogel, Arndt; Ikeda, Masafumi; Piscaglia, Fabio; Han, Kwang‐Hyub; Qin, Shukui; Minoshima, Yukinori; Kanekiyo, Michio; Ren, Min; Dairiki, Ryo; Tamai, Toshiyuki; Dutcus, Corina E.; Funahashi, Yasuhiro; Evans, T.R. Jeffry

doi:10.1093/annonc/mdy269.057

Cited by 26 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior investigations of the SHARP trial demonstrated that plasma concentrations of VEGF and Angiopoietin-2 are independent prognostic factors for survival, but none predicted a benefit from sorafenib over placebo. 30 Similar findings were reported also in the REFLECT 31 and in the CELESTIAL trials. 32 In contrast, plasma analyses from the RESORCE study indicated five proteins potentially involved in the inflammation process being predictive of regorafenib efficacy, but not prognostic.…”

supporting

confidence: 74%

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma

Personeni

Pressiani

Rimassa

2020

Health Science Reports

View full text Add to dashboard Cite

supporting

confidence: 74%

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma

Personeni

Pressiani

Rimassa

2020

Health Science Reports

View full text Add to dashboard Cite

“…Similar to the findings in the SHARP study, the biomarker program of the REFELCT study has so far not identified any clinical useful markers to select for either treatment, with the exception that in the small subgroup of patients with high baseline FGF21 OS was longer for lenvatinib compared to sorafenib. Higher VEGF, ANG2, and FGF21 baseline levels were associated with worse OS in both arms [34].…”

Section: Lenvatinib -Reflect Trialmentioning

confidence: 92%

Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma

Vogel

Saborowski

2020

Cancer Treatment Reviews

115

128

View full text Add to dashboard Cite

“…Recently, however, Finn R.S. compared serum biomarkers between patients treated with Lenvatinib and sorafenib; they presented the results of the Lenvatinib arm at the European Society for Medical Oncology (ESMO) [34], which showed decreased Ang-2 levels and increased levels of FGF19 and FGF23 with Lenvatinib therapy. Although our results were similar to Finn et al's unpublished data, our data showing that the combination of Ang-2 and FGF19 levels is a more sensitive marker for predicting disease progression in HCC patients being treated with Lenvatinib than the Ang-2 or FGF19 level alone is a novel finding.…”

Section: Discussionmentioning

confidence: 99%

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Chuma

Uojima

Numata

et al. 2020

Cancers

View full text Add to dashboard Cite

Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies against HCC. Levels of circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast growth factor 19 (FGF19), FGF23, and angiopoietin-2 (Ang-2) were measured using enzyme-linked immunosorbent assays. Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 vs. 0.810, respectively, p = 0.0002). Changes in FGF23 and VEGF levels at four weeks versus baseline, however, were not significantly different in responders versus non-responders. In multivariate analysis, the combination of serum FGF19-i and Ang-2-d was the most independent predictive factor for Lenvatinib response (Odds ratio, 9.143; p = 0.0012). Furthermore, this combination biomarker showed the greatest independent association with progression-free survival (Hazard ratio, 0.171; p = 0.0240). Early changes in circulating FGF19 and Ang-2 levels might be useful for predicting clinical response and progression-free survival in HCC patients on Lenvatinib therapy.

show abstract

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Cited by 26 publications

References 0 publications

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma

Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

Contact Info

Product

Resources

About